SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-21-023428
Filing Date
2021-02-16
Accepted
2021-02-16 12:07:48
Documents
1
Period of Report
2021-02-12

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm216121d3_3.html 3  
1 OWNERSHIP DOCUMENT tm216121d3_3.xml 3 4771
  Complete submission text file 0001104659-21-023428.txt   6869
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401 972-4-988-9488
Protalix BioTherapeutics, Inc. (Issuer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 1 DEXCEL STREET OR AKIVA L3 30600000
Business Address
Oren Dan (Reporting) CIK: 0001636701 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-33357 | Film No.: 21634766

Mailing Address 1 DEXCEL STREET OR AKIVA L3 3060000
Business Address 1 DEXCEL STREET OR AKIVA L3 3060000 97246364040
Dexcel Pharma Technologies Ltd. (Reporting) CIK: 0001720007 (see all company filings)

State of Incorp.: L3 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-33357 | Film No.: 21634767